Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.32 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.30 |
| ▸ | GLP1R | P43220 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177706 | 0.78 | — | — | |
| SCHEMBL2179886 | 0.78 | ENPP2 (0.31) | PTGS2PTGS1 | |
| SCHEMBL2179257 | 0.76 | PTGS2 (0.30) | PTGS2 | |
| SCHEMBL20554265 | 0.76 | — | — | |
| SCHEMBL20554185 | 0.76 | PTGS2 (0.31) | PTGS2 | |
| SCHEMBL2178591 | 0.73 | SMN1; SMN2 (0.36) | PTGS2PTGS1 | |
| SCHEMBL2176790 | 0.73 | FABP3 (0.32) | GLP1R | |
| SCHEMBL2180551 | 0.73 | — | — | |
| SCHEMBL2180703 | 0.73 | PTGS2 (0.32) | PTGS2PTGS1 | |
| SCHEMBL2177005 | 0.72 | POLB (0.38) | PTGS2PTGS1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4023640-A1 | PHENYLIMIDAZOLE COMPOUND | Otsuka Pharmaceutical Factory, Inc. (JP) | 2022-07-06 | — | — | EP | disclosed |
| CN-113200962-A | Phenylimidazole compounds | 株式会社大塚制药工场 | 2021-08-03 | — | — | CN | disclosed |
| CN-108430977-B | Phenylimidazole compounds | 株式会社大塚制药工场 | 2021-06-08 | — | — | CN | disclosed |
| US-10570117-B2 | Phenylimidazole compound | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2020-02-25 | — | — | US | disclosed |
| US-20180354930-A1 | PHENYLIMIDAZOLE COMPOUND | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-3401310-A1 | PHENYLIMIDAZOLE COMPOUND | Otsuka Pharmaceutical Factory, Inc. (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-20110166162-A1 | 1,2-Benzisothiazole Compounds Useful for Combating Animal Pests | BASF SE (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20080227796-A1 | 7-Amino-6-Hetaryl-1,2,4-Triazolo[1,5-A]Pyrimidine Compounds and the Use Thereof for Controlling Pathogenic Fungi | BASF AKTIENGESELLSCHAFT (DE) | 2008-09-18 | — | — | US | disclosed |
| US-20080132412-A1 | 7-Amino-6-Heteroaryl-1,2,4-Triazolo[1,5-A]Pyrimidines and Their Use for Controlling Harmful Fungi | BASF AKTIENGESELLSCHAFT (DE) | 2008-06-05 | — | — | US | disclosed |
| EP-1828190-A1 | 7-AMINO-6-HETEROARYL-1,2,4-TRIAZOLOÝ1,5-A¨PYRIMIDINES AND TO THE USE THEREOF FOR COMBATING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1828191-A2 | 7-AMINO-6-HETARYL-1,2,4-TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THE USE THEREOF FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066818-A2 | 7-AMINO-6-HETARYL-1,2,4-TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THE USE THEREOF FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006066799-A1 | 7-AMINO-6-HETEROARYL-1,2,4-TRIAZOLO[1,5-A]PYRIMIDINES AND TO THE USE THEREOF FOR COMBATING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570117-B2 | Phenylimidazole compound | LPL, PNLIP, LIPC | PTGS2 1956/4885PTGS1 1126/4885ABCC4 228/4885 |
| US-20080132412-A1 | 7-Amino-6-Heteroaryl-1,2,4-Triazolo[1,5-A]Pyrimidines and Their Use for Controlling Harmful Fungi | HINT1, PRF1, ERG28 | PTGS2 2158/4885PTGS1 1408/4885ABCC4 1917/4885 |
| US-20110166162-A1 | 1,2-Benzisothiazole Compounds Useful for Combating Animal Pests | GLRX3, CBR3, PRDX1 | PTGS2 3627/4885PTGS1 3330/4885ABCC4 385/4885 |
| US-20180354930-A1 | PHENYLIMIDAZOLE COMPOUND | PNLIP, PLIN1, HDAC11 | PTGS2 2676/4885PTGS1 1326/4885ABCC4 76/4885 |
| US-20080227796-A1 | 7-Amino-6-Hetaryl-1,2,4-Triazolo[1,5-A]Pyrimidine Compounds and the Use Thereof for Controlling Pathogenic Fungi | CYP8B1, CBR3, HDHD5 | PTGS2 975/4885PTGS1 915/4885ABCC4 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.